CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Alzamend Neuro, Inc. - ALZN CFD

0.9524
5.22%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0319
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023512 %
Charges from full value of position ($-4.47)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023512%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00129 %
Charges from full value of position ($0.25)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00129%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 1.0048
Open 0.9748
1-Year Change 11.99%
Day's Range 0.945 - 0.9848
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 21, 2025 0.9524 -0.0324 -3.29% 0.9848 0.9948 0.9448
Feb 20, 2025 1.0048 0.0300 3.08% 0.9748 1.0248 0.9747
Feb 19, 2025 0.9948 -0.1400 -12.34% 1.1348 1.1348 0.9148
Feb 18, 2025 1.0748 -0.0100 -0.92% 1.0848 1.0848 1.0648
Feb 14, 2025 1.0848 0.0000 0.00% 1.0848 1.0948 1.0748
Feb 13, 2025 1.0748 0.0100 0.94% 1.0648 1.0948 1.0548
Feb 12, 2025 1.0848 0.0100 0.93% 1.0748 1.1048 1.0448
Feb 11, 2025 1.0748 -0.0500 -4.45% 1.1248 1.1248 1.0548
Feb 10, 2025 1.1048 -0.0100 -0.90% 1.1148 1.1248 1.0848
Feb 7, 2025 1.1248 -0.0300 -2.60% 1.1548 1.1548 1.1048
Feb 6, 2025 1.1648 -0.0100 -0.85% 1.1748 1.1748 1.1448
Feb 5, 2025 1.1748 0.0400 3.52% 1.1348 1.1748 1.1148
Feb 4, 2025 1.1348 0.0200 1.79% 1.1148 1.1348 1.0948
Feb 3, 2025 1.1248 0.0300 2.74% 1.0948 1.1348 1.0848
Jan 31, 2025 1.1248 -0.0100 -0.88% 1.1348 1.1348 1.0948
Jan 30, 2025 1.1348 0.0400 3.65% 1.0948 1.1548 1.0948
Jan 29, 2025 1.1048 0.0000 0.00% 1.1048 1.1148 1.0948
Jan 28, 2025 1.1248 0.0100 0.90% 1.1148 1.1248 1.0948
Jan 27, 2025 1.1148 -0.0300 -2.62% 1.1448 1.1648 1.1048
Jan 24, 2025 1.1548 -0.0200 -1.70% 1.1748 1.1848 1.1348

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Alzamend Neuro, Inc. Company profile

About Alzamend Neuro Inc

Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company focused on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The Company's pipeline consists of two therapeutic drug candidates: AL001 and AL002. The AL001 is a cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing worldwide licenses from the University of South Florida Research Foundation, Inc. (licensor). AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing worldwide license from the licensor.

Financial summary

BRIEF: For the nine months ended 31 January 2022, Alzamend Neuro Inc revenues was not reported. Net loss increased from $3.8M to $8.5M. Higher net loss reflects Research and development - Bal increase from $953K to $3.2M (expense), Stock-based Compensation in SGA increase of 67% to $2.8M (expense), General and administrative - Bal increase from $547K to $1.1M (expense).

Industry: Biotechnology & Medical Research (NEC)

3480 Peachtree Road NE,
Second Floor, Suite 103
ATLANTA
GEORGIA 30326
US

People also watch

US100

21,594.40 Price
-2.120% 1D Chg, %
Long position overnight fee -0.0235%
Short position overnight fee 0.0013%
Overnight fee time 22:00 (UTC)
Spread 7.0

ETH/USD

2,787.72 Price
+5.690% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

XRP/USD

2.60 Price
+2.650% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01299

Gold

2,936.56 Price
-0.110% 1D Chg, %
Long position overnight fee -0.0149%
Short position overnight fee 0.0067%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 690,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading